Rheumatology Advance Access published online on August 9, 2006
Rheumatology, doi:10.1093/rheumatology/kel237
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Rheumatology, Medical University of Vienna, Vienna, Austria
* To whom correspondence should be addressed. Objectives. Despite early recognition and disease modifying anti-rheumatic drug (DMARD) treatment, a sizable proportion of early rheumatoid arthritis (RA) patients show radiological progression. This study was performed to determine the frequency of erosive arthritis and the pace of radiological progression in an inception cohort of patients with very early RA ( Methods. In order to determine possible prognostic factors for development of erosive disease, we linked the clinical features of these patients to radiological progression in a regression model. About 55 patients with RA and follow-up of at least 3 yrs were analysed. All had complete series of clinical, serological and radiographic assessments. Radiographs were scored according to the Larsen method. Results. Erosive disease developed in 63.6% of the patients over 3 yrs, with the majority (74.3%) appearing already in the first and 97.2% by the end of the second year. Among all variables available, rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) first presentation were the most predictive for both development of erosions and the degree of radiological progression. None of the clinical variables at the onset was useful to discriminate between erosive and non-erosive patients. In the final regression model, however, cumulative clinical activity substantially contributed to explaining radiological progression. Conclusion. Despite early treatment, substantial damage occurred in some patients and was associated with presence of strong ‘constitutive’ predictors such as anti-CCP and RF as well as presence of high long-term clinical disease activity as indicated by C-reactive protein (CRP), swollen joint counts and the absence of a good clinical response (assessed by the failure to achieve lasting low disease activity).
Received February 19, 2006
Accepted June 2, 2006
Original Papers
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease
K. P. Machold 1 *, T. A. Stamm 1, V. P. K. Nell 1, S. Pflugbeil 2, D. Aletaha 3, G. Steiner 1, M. Uffmann 4, and J. S. Smolen 5
2 2nd Medical Department, Hietzing Municipal Hospital, Vienna, Austria
3 Mark O Hatfield Clinical Research Center, NIAMS/NIH, Bethesda, USA
4 Department of Radiology, Medical University of Vienna, Vienna, Austria
5 Department of Rheumatology, Medical University of Vienna, Vienna, Austria; 2nd Medical Department, Hietzing Municipal Hospital, Vienna, Austria
K. P. Machold, E-mail: Klaus.machold{at}meduniwien.ac.at
Abstract 
3 months after onset of symptoms).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Vastesaeger, S. Xu, D. Aletaha, E. W. St Clair, and J. S. Smolen A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis Rheumatology, September 1, 2009; 48(9): 1114 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. MJAAVATTEN, A. J. HAUGEN, K. HELGETVEIT, H. NYGAARD, G. SIDENVALL, T. UHLIG, and T. K. KVIEN Pattern of Joint Involvement and Other Disease Characteristics in 634 Patients with Arthritis of Less Than 16 Weeks' Duration J Rheumatol, July 1, 2009; 36(7): 1401 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. RENESES, M. F. GONZALEZ-ESCRIBANO, A. FERNANDEZ-SUAREZ, L. PESTANA, B. DAVILA, I. WICHMANN, and A. GARCIA The Value of HLA-DRB1 Shared Epitope, -308 Tumor Necrosis Factor-{alpha} Gene Promoter Polymorphism, Rheumatoid Factor, Anti-Citrullinated Peptide Antibodies, and Early Erosions for Predicting Radiological Outcome in Recent-Onset Rheumatoid Arthritis J Rheumatol, June 1, 2009; 36(6): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K P Liao, K L Batra, L Chibnik, P H Schur, and K H Costenbader Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis Ann Rheum Dis, November 1, 2008; 67(11): 1557 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Weiss, A. Ehlin, S. M. Montgomery, M. C. Wick, A. Stark, and P. Wretenberg Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54 579 Swedish RA inpatients Rheumatology, April 1, 2008; 47(4): 491 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Anzilotti, L. Riente, F. Pratesi, D. Chimenti, A. Delle Sedie, S. Bombardieri, and P. Migliorini IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders Rheumatology, October 1, 2007; 46(10): 1579 - 1582. [Abstract] [Full Text] [PDF]
|
|